Research Article

Association of Polymorphisms of Genes Involved in Lipid Metabolism with Blood Pressure and Lipid Values in Mexican Hypertensive Individuals

Blanca Estela Ríos-González, Bertha Ibarra-Cortés, Guadalupe Ramírez-López, José Sánchez-Corona, and María Teresa Magaña-Torres

1 División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada No. 800, Colonia Independencia, JAL, Mexico
2 Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada No. 950, Colonia Independencia, 44348 Guadalajara, JAL, Mexico
3 Instituto de Genética Humana “Enrique Corona Rivera”, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada No. 950, Colonia Independencia, 44348 Guadalajara, JAL, Mexico
4 Unidad de Investigación Epidemiológica y en Servicios de Salud del Adolescente, Instituto Mexicano del Seguro Social, Avenida Tonalá 121, 45400 Tonalá, JAL, Mexico
5 División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada No. 800, Colonia Independencia, 44340 Guadalajara, JAL, Mexico

Correspondence should be addressed to María Teresa Magaña-Torres; maganamt@yahoo.com.mx

Received 18 September 2014; Revised 12 November 2014; Accepted 13 November 2014; Published 21 December 2014

Academic Editor: Claudio Letizia

Copyright © 2014 Blanca Estela Ríos-González et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hypertension and dyslipidemia exhibit an important clinical relationship because an increase in blood lipids yields an increase in blood pressure (BP). We analyzed the associations of seven polymorphisms of genes involved in lipid metabolism (APOA5 rs3135506, APOB rs1042031, FABP2 rs1799883, LDLR rs5925, LIPC rs1800588, LPL rs328, and MTTP rs1800591) with blood pressure and lipid values in Mexican hypertensive (HT) patients. A total of 160 HT patients and 160 normotensive individuals were included. Genotyping was performed through PCR-RFLP, PCR-AIRS, and sequencing. The results showed significant associations in the HT group and HT subgroups classified as normolipemic and hyperlipemic. The alleles FABP2 p.55T, LIPC −514T, and MTTP −493T were associated with elevated systolic BP. Five alleles were associated with lipids. LPL p.474X and FABP2 p.55T were associated with decreased total cholesterol and LDL-C, respectively; APOA5 p.19W with increased HDL-C; APOA5 p.19W and FABP2 p.55T with increased triglycerides; and APOB p.4181K and LDLR c.1959T with decreased triglycerides. The APOB p.E4181K polymorphism increases the risk for HT (OR = 1.85, 95% CI: 1.17–2.93; \( P = 0.001 \)) under the dominant model. These findings indicate that polymorphisms of lipid metabolism genes modify systolic BP and lipid levels and may be important in the development of essential hypertension and dyslipidemia in Mexican HT patients.

1. Introduction

Hypertension and dyslipidemia are major global public health problems because they are highly prevalent, contribute to the development of cardiovascular disease, and are components of metabolic syndrome. In Mexico, 26.6% of the working-age population is hypertensive (HT), 48.7% exhibits high total cholesterol (TC) levels (≥200 mg/dL), and 57.3% displays high triglyceride (TG) concentrations (≥150 mg/dL) [1]. Essential hypertension (EH) is a multifactorial disease, whose development involves environmental and genetic factors. A significant percentage (30%–60%) of blood pressure (BP) variation is due to genetic factors, and at least 69 genes have been associated with EH [2].

A group of genes that have been less well studied but may play an important role in EH development are those encoding
proteins involved in lipid metabolism. Hypertension and dyslipidemia show an important clinical relationship because an increase in nonesterified fatty acids (NEFAs) (lipoprotein metabolism products) increases BP, but, in normal conditions, the endocrine, sympathetic, and parasympathetic systems stabilize BP [3]. However, in the presence of chronic hyperlipidemia, such regulatory mechanisms are insufficient, and the sustained increase in NEFAs directly affects cardiac output and peripheral resistance, which are important hemodynamic variables that regulate BP cardiac output can be altered by a decrease in the sensitivity of baroreceptors, increased synthesis of catecholamine, and an increased heart rate [3, 4], while peripheral resistance may increase by alpha-1 adrenergic receptor hypersensitivity [5], endothelial dysfunction, and atherosclerotic plaque formation [6].

Considering the close relationship between BP and blood lipid levels, we selected seven polymorphisms of seven genes that have mainly been associated with cardiovascular disease, atherosclerosis, dyslipidemias, and obesity. (1) APOA5 p.S19W (rs3135506): the APOAV protein plays an important role in triglyceride (TG) metabolism, and the p.19W allele is negatively correlated with the secretion of this protein [7] and has been associated with increased TG and high-density lipoprotein cholesterol (HDL-C) levels [8, 9]. (2) APOB p.E4181K (rs1042031): the APOB protein is the main apolipoprotein found in chylomicrons (CM) and low-density cholesterol lipoproteins (LDL-C). The p.4181K allele is positively correlated with HDL-C [10]. (3) FABP2 p.A55T (rs1799883): the FABP2 protein is involved in fatty acid use in the intestine, and the p.55T allele shows a higher affinity for fatty acids; hence, it promotes TG-rich lipoprotein formation [11]. (4) LDLR c.1959C>T (rs5925): the LDL receptor is involved in cholesterol homeostasis through lipoprotein endocytosis, and the c.1959T allele is associated with low TC, LDL-C, HDL-C, and TG in different groups of individuals [12, 13]. (5) LIPC −514 C>T (rs1800588): the LIPC protein functions as both a lipase and ligand, and the −514T allele has been positively correlated with HDL-C levels and negatively correlated with LIPC activity [14]. (6) LPL p.S474X (rs328): the LPL protein hydrolyses TG from very low-density lipoprotein cholesterol (VLDL-C) and CM. The mutated allele increases this enzymatic activity; hence, it improves TG-rich lipoprotein depuration [15]. (7) MTTP −493 G>T (rs1800591): MTTP is involved in VLDL-C and CM assemblage and secretion, and the homozgyous genotype −493 TT has been associated with low TC, LDL-C, APOB, and MTTP mRNA levels [16].

The aim of the current study was to analyze the relationship of the APOA5 p.S19W and APOB p.E4181K, FABP2 p.A55T, LDLR c.1959C>T, LIPC −514 C>T, LPL p.S474X, and MTTP −493 G>T polymorphisms with blood pressure and lipid levels in Mexican HT patients and in subgroups classified according to the presentation of different dyslipidemias.

2. Materials and Methods

2.1. Study Population. A total of 716 unrelated individuals aged 19–81 years were recruited from Family Medicine Unit number 93 and the Centro de Investigación Biomédica de Occidente of the Instituto Mexicano del Seguro Social in the metropolitan area of Guadalajara, Jalisco, Mexico. Blood samples were drawn from each of the subjects after at least 12 hours of fasting and without drinking alcohol for the preceding 72 hours. Two tubes of blood were collected; the first was used for biochemical testing, and the second was used to extract DNA. Biochemical measurements were performed using enzymatic methods with commercial kits and a semiautomated ALS 2000 spectrophotometer. Tecno diagnostics (Anaheim, CA), Trinder GOD-POD, Spinreact (Esteve de Bas, Girona, Spain), and AccuBind kits (Lake Forest, CA) were employed to determine the lipid profile (TC, LDL-C (using the Friedewald formula), HDL-C, and TG), glucose, and insulin, respectively. Blood pressure was measured according to the criteria proposed by NOM-030-SSA2-2009 [17].

From the total subjects (n = 716), we selected 320 individuals, mainly considering their blood pressure values, personal clinical history, age, and sex. The subjects included in the study consisted of 160 HT patients with systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg [17] (121 women and 39 men), with a mean age of 47 ± 10 years (range 23–69 years), and 160 normotensive subjects (NT) with systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg [17] (114 women and 46 men), with a mean age of 47 ± 11 years (range 20–81 years). Both groups were paired by 10-year age range and by sex, and no significant differences were identified based on the age (P = 0.69) or sex (P = 0.69) variables. None of the included individuals fulfilled all of the criteria for metabolic syndrome. The protocol was designed based on the guidelines outlined in the Declaration of Helsinki. It was reviewed and approved by the institute's ethics committee. The participants were informed of the study objectives and signed a consent letter.

2.2. Molecular Analysis. DNA was extracted from peripheral blood using standard procedures. Polymorphism genotyping was performed by means of three techniques: (a) polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, to identify the APOB p.E4181K, FABP2 p.A55T, LDLR c.1959C>T, and LPL p.S474X sites; (b) artificial introduction of restriction sites (PCR-AIRS), to detect APOA5 p.S19W and MTTP −493G>T; and (c) sequencing, for the LIPC −514C>T site. The primers used to identify the MTTP −493G>T polymorphism were designed with Oligo 6.0 software (forward 5’ CTA GTG TGC TAA TGA CAG ACA ATG C 3’ and reverse 5’ GGA TTT AAA TTT AAA C 3’). A 155bp fragment was amplified and digested with the Hph I enzyme. The PCR mixture included 13.3 ng/μL genomic DNA, 0.46 pg/μL of each primer, 0.204 mM of each dNTP, 1.5 mM MgCl₂, and 0.04 U/μL Taq polymerase. The final reaction volume was 15 μL. The amplification program was as follows: initial denaturation for 4 min at 95°C, followed by 30 cycles of denaturation at 95°C for 25 sec, annealing at 91°C for 40 sec, and extension at 72°C for 45 sec, with a final extension at 72°C for 7 min.

The PCR and amplification conditions for the remaining six sites were described elsewhere [18]. FABP2 p.A55T,
which was previously identified through sequencing [18], was

genotyped in this work using the restriction enzyme Hha I.
The samples employed as digestion controls were confirmed

through sequencing in an ABI PRISM 310 sequencer using

the BigDye Terminator v3.1 kit and following the manufac-
turer’s instructions.

2.3. Statistical Analyses. The genotypic and allelic frequencies

for the seven polymorphisms were established through direct

counting. The frequencies were compared among the groups

(NT and HT) using the chi-square or Fisher exact test.
The effect of the polymorphisms on BP and lipid profile

levels was determined in the group of HT patients and the

HT subgroups classified as normolipemic and hyperlipemic

according to lipid profile. An analysis of variance (ANOVA)

was performed for the genotypes, followed by post hoc tests

(Bonferroni or Dunnett, in relation to variance homogene-

ity). The mean differences between alleles were calculated

with Student’s t-test. The Pearson (for quantitative and

normally distributed variables) and Spearman (for qualitative

variables) correlations and multiple linear regression models

were generated. A value of \( P < 0.05 \) was considered statistically significant. The analyses were

performed using SPSS v.18.0.

3. Results

3.1. Genotypic and Allelic Frequencies. The genotype and

allele frequency distributions of the seven polymorphisms are

shown in Table 1. All three possible genotypes were observed

at each site and exhibited heterogeneous frequencies. The

frequencies of the mutant genotypes of FABP2 p.A55T, LDLR

c.1959C>T, and LIPC c.−514T>G alleles were approximately 30% in the HT and NT groups. The four remaining polymorphisms
displayed frequencies lower than 5%. In both of the studied

groups, the mutant alleles of LDLR c.1959T and LIPC c.−514T

were more frequent than the wild-type alleles; in contrast LPL

c.474X mutant allele did not exceed a 10% frequency.

Comparison of the genotypic and allelic frequencies

between the groups revealed statistically significant differ-

ces only for the APOB p.E4181K polymorphism (\( P = 0.01 \)

and \( P = 0.04 \), resp.) due to a higher percentage of heterozygotes in the HT group (Table 1).

3.2. Effect of the Polymorphisms on the Lipid Profile and

Blood Pressure of HT Patients. In the association analysis

between the polymorphisms versus the variables, 70 patients

to the total HT group receiving antihypertensive and/or

hypolipidemic treatments were excluded.

Considering all of the HT patients not receiving drug
treatment (\( n = 90 \)), the following significant associations

with TC and TG were observed. Subjects with the LPL c.474X

allele showed lower TC concentrations (185.0 mg/dL) than

the patients with the p.474S allele (203.0 mg/dL, \( P = 0.006 \)),

while individuals with the FABP2 p.55T allele exhibited

higher TG concentrations (161.2 mg/dL) than the patients

with the p.55A allele (131.2 mg/dL; \( P = 0.006 \)). A significant

multiple linear regression model with the FABP2 p.55T and

LDLR c.1959T alleles to explain TG levels was established

(Table 4).

In regard to blood pressure, subjects carrying the LIPC

−514T allele showed higher SBP values (151.2 mm Hg) than

patients with the −514C allele (146.2 mm Hg), \( P = 0.039 \).

3.3. Hypertensive Patients Classified as Normolipemic and

Hyperlipemic: Effect of the Polymorphisms on the Lipid Profile

and Blood Pressure. All of the studied polymorphisms are

located in genes that modulate lipid metabolism and have

been associated mainly with dyslipidemia and/or cardiovas-
cular disease. Dyslipidemias distribution in HT patients is

shown in Table 2 and the classification was done according

the NOM-037-SSA2-2002 [19].

Association analysis was performed in two subgroups of

hypertensive patients, normolipemic (without dyslipi-
demia) and hyperlipemic (with dyslipidemia) (Table 2). Normolipemic subgroup was integrated by 50 patients, with

a mean age of 50 ± 11 years (range 30–69 years). Hyperlipemic

subgroup was formed by 40 patients, with a mean age of

45 ± 11 years (23–69 years). Age variable was not significantly
different between subgroups (\( P = 0.60 \)).

Analysis of the two subgroups showed many significant

results. However, we present only those for which a multiple

linear regression model was generated and showed significant

values for ANOVA, Student’s t-test, or Spearman correlation.

Table 3 provides the ANOVA, Student’s t-test, and Spearman

correlation results; two ANOVA nonsignificant \( P \) values were

included to indicate trends (FABP2 p.55T allele for TG and

SBP with \( P = 0.09 \) and \( P = 0.08 \), resp.). The multiple linear

regression models for each polymorphism and quantitative

variable are presented in Table 4. To avoid duplicate data, the

values of the association tests are not provided in the text and

are only shown in tables.

APOA5 p.S19W. The p.19W allele was associated with sig-
nificant increases in HDL-C and TG in normolipemic and

hyperlipemic HT patients, respectively.

APOB p.E4181K. We detected one significant association in the

normolipemic subgroup; the HT patients carrying the

p.4181K allele showed a lower TG concentration than those

bearing the p.4181E allele.

FABP2 p.A55T. This polymorphism exhibited an association

with three variables. TG and SBP levels were increased signifi-
cantly in presence of the mutated allele p.55T in hyperlipemic

and normolipemic subgroups, respectively; while LDL-C

values were lower in hyperlipemic patients with p.55T versus

p.55A.

LPL p.S474X C>G. The p.474X allele was associated with

lower TC levels in HT hyperlipemic patients.

MTTP c.−493 G>T. Hyperlipemic patients carrying the c.−493T

allele showed statistically higher SBP levels than those with

the c.−493G allele (Tables 3 and 4).
Table 1: Frequencies of genotypic and allelic polymorphisms in hypertensive and normotensive subjects.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n=160</strong></td>
<td><strong>n=160</strong></td>
<td><strong>n=158</strong></td>
<td><strong>n=160</strong></td>
<td><strong>n=154</strong></td>
<td><strong>n=160</strong></td>
<td><strong>n=160</strong></td>
<td><strong>n=158</strong></td>
</tr>
<tr>
<td><strong>Genotype</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SS</td>
<td>97</td>
<td>60.6</td>
<td>88</td>
<td>55.0</td>
<td>CC 36</td>
<td>CC 38</td>
<td>SS 142</td>
</tr>
<tr>
<td>EE</td>
<td>88</td>
<td>55.0</td>
<td>75</td>
<td>47.5</td>
<td>CT 73</td>
<td>CT 67</td>
<td>GG 106</td>
</tr>
<tr>
<td>AA</td>
<td>57</td>
<td>36.1</td>
<td>57</td>
<td>36.1</td>
<td>TT 51</td>
<td>TT 49</td>
<td>GG 106</td>
</tr>
<tr>
<td>WW</td>
<td>4.4</td>
<td>31.9</td>
<td>5.2</td>
<td>31.9</td>
<td>TT 49</td>
<td>TT 49</td>
<td>GG 106</td>
</tr>
<tr>
<td><strong>n=320</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=316</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=308</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=316</strong></td>
<td><strong>n=316</strong></td>
</tr>
<tr>
<td>** Allele**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>250</td>
<td>77.1</td>
<td>243</td>
<td>75.9</td>
<td>155</td>
<td>49.1</td>
<td>S 250</td>
</tr>
<tr>
<td>E</td>
<td>70</td>
<td>22.9</td>
<td>77</td>
<td>24.1</td>
<td>175</td>
<td>54.7</td>
<td>E 151</td>
</tr>
<tr>
<td>W</td>
<td>4.4</td>
<td>33.1</td>
<td>53</td>
<td>33.3</td>
<td>44</td>
<td>27.5</td>
<td>W 7 4.4</td>
</tr>
<tr>
<td><strong>n=320</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=314</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=318</strong></td>
</tr>
<tr>
<td><strong>Genotype</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SS</td>
<td>100</td>
<td>62.5</td>
<td>111</td>
<td>69.4</td>
<td>CC 34</td>
<td>CC 35</td>
<td>SS 135</td>
</tr>
<tr>
<td>EE</td>
<td>111</td>
<td>69.4</td>
<td>111</td>
<td>69.4</td>
<td>CT 82</td>
<td>CT 78</td>
<td>GG 106</td>
</tr>
<tr>
<td>AA</td>
<td>69.4</td>
<td>44.7</td>
<td>71</td>
<td>44.7</td>
<td>TT 44</td>
<td>TT 44</td>
<td>TT 135</td>
</tr>
<tr>
<td>WW</td>
<td>4.4</td>
<td>33.3</td>
<td>53</td>
<td>33.3</td>
<td>TT 44</td>
<td>TT 44</td>
<td>TT 135</td>
</tr>
<tr>
<td><strong>n=320</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=320</strong></td>
<td><strong>n=314</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=318</strong></td>
<td><strong>n=318</strong></td>
</tr>
<tr>
<td><strong>Allele</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S</td>
<td>253</td>
<td>79.1</td>
<td>264</td>
<td>82.5</td>
<td>177</td>
<td>55.7</td>
<td>S 253</td>
</tr>
<tr>
<td>E</td>
<td>67</td>
<td>20.9</td>
<td>67</td>
<td>17.1</td>
<td>141</td>
<td>44.3</td>
<td>E 56</td>
</tr>
<tr>
<td>W</td>
<td>4.4</td>
<td>33.3</td>
<td>53</td>
<td>33.3</td>
<td>170</td>
<td>53.1</td>
<td>W 53</td>
</tr>
<tr>
<td><strong>P genotype</strong></td>
<td>0.93</td>
<td>0.01</td>
<td>0.19</td>
<td>0.58</td>
<td>0.52</td>
<td>0.77</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>P allele</strong></td>
<td>0.85</td>
<td>0.04</td>
<td>0.23</td>
<td>0.69</td>
<td>0.86</td>
<td>0.27</td>
<td>0.65</td>
</tr>
</tbody>
</table>

*Due to a lack of DNA, these samples were not screened. HT: hypertensive patients. NT: normotensive subjects.
Table 2: Distribution of dyslipidemias in hypertensive patients.

<table>
<thead>
<tr>
<th></th>
<th>Without</th>
<th>%</th>
<th>With</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>aHypercholesterolemia</td>
<td>66</td>
<td>73.3</td>
<td>24</td>
<td>26.7</td>
</tr>
<tr>
<td>bLDL-C ≥ 130 mg/dL</td>
<td>51</td>
<td>56.7</td>
<td>39</td>
<td>43.3</td>
</tr>
<tr>
<td>cHypertriglyceridemia</td>
<td>81</td>
<td>90.0</td>
<td>9</td>
<td>10.0</td>
</tr>
<tr>
<td>dMixed hyperlipidemia</td>
<td>83</td>
<td>92.2</td>
<td>7</td>
<td>7.8</td>
</tr>
<tr>
<td>eHypoalphalipoproteinemia</td>
<td>63</td>
<td>70.0</td>
<td>27</td>
<td>30.0</td>
</tr>
<tr>
<td>fDyslipidemia</td>
<td>50</td>
<td>55.6</td>
<td>40</td>
<td>44.4</td>
</tr>
</tbody>
</table>

*Total cholesterol (TC) > 200 mg/dl, LDL-C > 130 mg/dL, and triglycerides (TG) < 200 mg/dL; bLDL-C ≥ 130 mg/dL; TC < 200 mg/dL, LDL-C < 130 mg/dL, and TG > 200 mg/dL; dLDL-C ≥ 130 mg/dL, and TG ≥ 200 mg/dL; eHDL-C < 35 mg/dL; and fpresence of any dyslipidemia (hypercholesterolemia or hypertriglyceridemia or mixed hyperlipidemia).

3.4. Multiple Linear Regression Models. In total, nine distinct multiple linear regression models with statistically significant differences were generated with genotypes and alleles data; in Table 4, the results obtained with the alleles are shown. An integrated model with two polymorphisms FABP2 p.A55T and LDLR c.1959C>T, explaining TG levels, was observed in the total group of hypertensive (n = 90) and hyperlipemic subgroup. The eight remaining models included only one polymorphism. The TG variable presented a greater number of significant models (Table 4).

3.5. Logistic Regression Models. In this analysis, we observed two models. The first was observed for APOB p.E4181K, which increased the risk of developing essential hypertension under the dominant model (EK+KK vs. EE) (OR = 1.85; 95% CI: 1.2–2.9 and P = 0.01). The second model showed that HT patients carrying the APOA5 p.19W allele exhibit an increased risk of presenting mixed hyperlipidemia (OR = 8.8; 95% CI: 1.76–44.0; P = 0.02) under the recessive model (WW vs. SW+SS).

4. Discussion

Essential hypertension is a multifactorial disease with a strong genetic component; therefore, genes corresponding to different metabolic routes have been explored. Because increased blood lipid levels are known to result in an increase in blood pressure, in the present work, we analyzed seven polymorphisms of genes involved in lipid metabolism in HT patients to examine their role in the development of essential hypertension and dyslipidemias.

It is important to note that when the association analysis was performed in the entire HT group, only a few significant results were observed. However, the analysis of the HT patients classified according to lipid levels revealed more significant associations between the polymorphisms and diverse variables. Studies examining these polymorphisms in different populations have revealed heterogeneous results. A possible explanation is that these differences occur because most of the authors did not analyze the data by separating individuals according to dyslipidemia.

4.1. Genotypic and Allelic Frequencies. In the genotypic and allelic frequency distribution analyses for the HT and NT groups, we observed significant differences for the polymorphism APOB p.E4181K, based on the presence of more heterozygotes in the HT group (41.9% versus 23.3%). Other studies have analyzed this polymorphism in relation to cardiovascular disease, but the authors did not observe significant differences in the genotype and/or allele distribution [20, 21]. We compared the results for the seven polymorphisms with the reported frequencies in the general Mexican population [18, 22]. The analysis showed similar genotypic frequency distributions for the general population and NT individuals (P > 0.05). However, we observed significant differences between the general population and the HT group for three polymorphisms: the APOB p.E4181K site (P = 0.008), FABP2 p.A55T (P = 0.002), and the LIPC −514C>T polymorphism (P = 0.04). Only two of the seven analyzed polymorphisms have been studied in HT patients: LDLR c.1959C>T (Chinese population) [12] and LPL p.S474X (Chinese and Caucasian populations) [23]; similar to the results of the present study, the authors did not report significant differences in the genotypic and allelic frequency distribution.

4.2. Distribution of Dyslipidemias in HT Patients. In Mexico, dyslipidemias and essential hypertension are the most common risk factors for the development of cardiovascular disease in the general adult population [24, 25]. In this study more than 40% of the subjects exhibited some form of dyslipidemia (hypercholesterolemia or hypertriglyceridemia or mixed hyperlipidemia), which indicates a significant health problem. Various reports have revealed that one of the most frequent dyslipidemias in the Mexican population is hypoalphalipoproteinemia, and similar results were obtained in this study. Low HDL-C levels in HT patients have also been observed in other populations at frequencies higher than 30% [26]. Although a clinical finding of hypoalphalipoproteinemia does not represent a health problem by itself, it is an important risk factor for developing cardiovascular disease and metabolic syndrome when associated with high TG and TC levels. Furthermore, in patients with hypertension, several coincident biochemical alterations can increase cardiovascular risk and complicate hypertension management.

4.3. Effect of the Polymorphisms on the Lipid Profile and Blood Pressure of Hypertensive Patients and Normolipemic and Hyperlipemic Subgroups

APOA5 p.S19W. The APOAV protein is a component of the lipoproteins HDL-C, VLDL-C, and CM; it activates LPL for efficient TG lipolysis. In this study, the p.19W allele was associated with increased HDL-C in normolipemic HT patients (Tables 3 and 4). This association between high HDL-C levels and the p.19W allele has been reported in healthy subjects from Puerto Rico [8].

High TG levels associated with the p.19W allele were observed in hyperlipemic HT patients. Similar results have been detected in young, healthy Caucasian males [9], Spanish subjects in the ICARIA project [27], and Caucasian children 6–8 years old [28]. This association was also reflected in

...
Table 3: Results of ANOVA, Student’s $t$, and correlation tests between polymorphisms and quantitative variables in normolipemic and hyperlipemic hypertensive patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype</th>
<th>Genotype</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>$APOA5$ p.S19W</td>
<td>ANOVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>WW</td>
<td>67.0</td>
<td>0.000</td>
<td>Normolipemic</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>WW</td>
<td>221.0</td>
<td>0.032</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>Student’s $t$-test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>WW</td>
<td>67.0</td>
<td>0.001</td>
<td>Normolipemic</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>WW</td>
<td>212.0</td>
<td>0.049</td>
<td>Normolipemic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype</th>
<th>Genotype</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>$APOB$ p.E4181K</td>
<td>ANOVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>WW</td>
<td>88.3</td>
<td>0.006</td>
<td>Normolipemic</td>
</tr>
<tr>
<td>Student’s $t$-test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>WW</td>
<td>83.2</td>
<td>0.003</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype</th>
<th>Genotype</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>$FABP2$ p.A55T</td>
<td>ANOVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>AA</td>
<td>15.0</td>
<td>0.018</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>AA</td>
<td>158.0</td>
<td>0.082</td>
<td>Normolipemic</td>
</tr>
<tr>
<td>Student’s $t$-test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>AA</td>
<td>15.0</td>
<td>0.018</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>AA</td>
<td>158.0</td>
<td>0.082</td>
<td>Normolipemic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype</th>
<th>Genotype</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>$LPL$ p.S474X</td>
<td>ANOVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>XX</td>
<td>236.0</td>
<td>0.035</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>Student’s $t$-test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>XX</td>
<td>236.0</td>
<td>0.035</td>
<td>Hyperlipemic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Genotype</th>
<th>Genotype</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>$MTTP$ −493 G&gt;T</td>
<td>ANOVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>GT</td>
<td>142.4</td>
<td>0.002</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>Student’s $t$-test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>GT</td>
<td>142.4</td>
<td>0.002</td>
<td>Hyperlipemic</td>
</tr>
</tbody>
</table>

TG: triglycerides; TC: total cholesterol; SBP: systolic blood pressure; *Nonsignificant $P$ value, but significant in the remaining statistical tests.

Table 4: Multiple linear regression models observed in normolipemic and hyperlipemic hypertensive patients.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Allele</th>
<th>Constant</th>
<th>$B$</th>
<th>$P$</th>
<th>Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mg/dL)</td>
<td></td>
<td>234.1</td>
<td>−44.5</td>
<td>0.039</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td></td>
<td>162.2</td>
<td>−20.7</td>
<td>0.024</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td></td>
<td>43.6</td>
<td>8.7</td>
<td>0.007</td>
<td>Normolipemic</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td></td>
<td>183.5</td>
<td>52.0</td>
<td>0.023</td>
<td>Hyperlipemic</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td></td>
<td>147.1</td>
<td>7.9</td>
<td>0.007</td>
<td>Normolipemic</td>
</tr>
</tbody>
</table>

TC: total cholesterol; TG: triglycerides; SBP: systolic blood pressure.
the logistic regression analysis because, in the HT group, the p.19W allele (under recessive model) increased the risk of presenting mixed hyperlipidemia by more than 8-fold.

In general, the findings of increased HDL-C and TG are consistent with the function of the APOA5 p.19W variant because reduced secretion of the protein decreases LPL activity [7], increasing TG levels in plasma. Moreover, APOAV is a component of HDL-C, and APOAV deficiency may reduce the metabolism of these particles, which increases their blood concentration.

**APOB p.E4181K.** APOB is the primary protein found in VLDL-C, IDL-C, and LDL-C; thus, it is important for cholesterol homeostasis. The APOB p.E4181K polymorphism is located in the proximal portion of the terminal carboxyl and increases LDL-C catabolism, with a consequent decrease of LDL-C and APOB levels [10]. In the present study, the p.4181K allele was associated with lower TG levels in normolipemic HT patients; this association has not been observed in other populations. The association between low TC and LDL-C levels and the p.4181K allele has been demonstrated in most populations studied to date. However, the literature is inconsistent regarding whether the p.4181K allele is protective or is a risk factor for cardiovascular diseases, as both models have been observed [10]. In this work we found a risk of developing hypertension conferred by p.4181K allele, with an OR = 1.85; 95% CI: 1.2–2.9; P = 0.01, which is similar to the findings of a meta-analysis of 30 case-control reports where the risk of developing cardiovascular disease and myocardial infarction was evaluated, and the authors obtained an OR of 1.73 (95% CI: 1.19–2.50) [29]. Thus, we suggest that the p.4181K allele increases the risk of developing cardiovascular disease, myocardial infarction, and hypertension; however, its pathway of action must be different from that related to lipids because this allele is associated with lower TG, TC, and LDL-C concentrations.

**FABP2 p.A55T.** The FABP2 p.A55T polymorphism has been extensively studied and referenced in the literature. The p.55T allele results in a higher affinity of this protein for long-chain fatty acids and, hence, greater absorption of such fatty acids [11]. In this study, the p.55T allele was associated with increased SBP in normolipemic HT patients, which differs from the findings of de Luis, who observed a decrease in SBP in nondiabetic obese subjects [30]. However, an association between the mutated allele and an increase in TG was observed in the HT patients and hyperlipemic subgroup and has been reported previously [31, 32]. This association is consistent with the increase in fatty acid absorption found in individuals with the p.55T allele and therefore enhances TG-rich lipoprotein formation [11]. Moreover, the studied groups in which this association had been observed also exhibit low HDL-C, as found in our patients with hypophilalipoproteinemia.

**LDLR c.1959C>T.** The c.1959T allele was associated with low TG levels in HT patients and hyperlipemic subgroup, in a multiple linear regression model (Table 4). In general population of China, this allele has been associated with lower TC, LDL-C, and TG concentrations [12, 13].

**LIPC −514 C>T.** One of the primary functions of hepatic lipase is to hydrolyze TG and phospholipids, and hepatic lipase is an important enzyme in HDL-C metabolism [14]. HT patients group with the −514T allele exhibited higher SBP values compared with those carrying the −514C allele. To our knowledge, this is the first study to analyze this polymorphism in HT patients and to assess its association with blood pressure.

**LPL p.S474X.** The primary function of LPL is to hydrolyze TG from CM and VLDL-C. It has been shown that the p.474X allele increases LPL enzymatic activity; hence, it has been associated with decreased plasma TG and increased HDL-C [15]. In the present work, in the HT and HT hyperlipemic groups, the p.474X allele was associated with lower TC levels, as previously observed in a meta-analysis. The mutated allele has also been associated with lower TG and SBP levels as well as higher HDL-C levels [33]. Consistent with such results, the presence of the p.474X allele has shown in previous reports a lower risk for developing coronary heart disease [33] and hypertension (OR 0.78; 95% CI: 0.62–0.98, P = 0.03) [34].

**MTTP −493 G>T.** The MTTP enzyme is involved in the assembly and secretion of VLDL-C, which transports TG, cholesterol, and phospholipids [16]. In this study, the −493T allele was associated with increased SBP in HT hyperlipemic subgroup, which has not been previously reported in the literature. However, in healthy males and hypercholesterolemia patients, the mutated allele has been associated with low TC [16] and TG levels [35], respectively.

### 5. Conclusions

We highlight three important conclusions. (i) The APOB p.E4181K polymorphism (under the dominant model) is associated with an increased risk for hypertension. (ii) Three polymorphisms were found to be associated with systolic blood pressure levels in HT patients. Increased SBP was associated with the FABP2 p.55T, LIPC −514T, and MTTP −493T alleles. (iii) Modifications of the four different lipids studied herein were observed to be correlated with certain polymorphisms. Total cholesterol is decreased in subjects with the LPL p.474X allele; LDL-C is decreased with FABP2 p.55T; HDL-C is increased with APOA5 p.19W; and triglycerides are increased with APOA5 p.19W and FABP2 p.55T but decreased with APOB p.4181K and LDLR c.1959T. These findings indicate that polymorphisms of lipid metabolism genes modify systolic blood pressure and lipid levels and may be important for the development of essential hypertension and dyslipidemia in Mexican HT patients.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.
Acknowledgments

This study was supported by the Consejo Nacional de Ciencia y Tecnología (CONACYT)/Fondos Sectoriales Sector Salud 2005-C02-14410. The authors gratefully acknowledge the investigators of the GEMHAS group: Maria Cristina Morán Moguel, Javier Perea Díaz, Silvia Esperanza Flores Martinez, Alejandra Guadalupe García Zapién, Caridad Aurea Leal Cortés, José Z. Parra Carrillo, Salvador Fonseca Reyes, José Amado Espinosa Lobato, Alejandro Bravo Cuellar, Maria Elena Aguilar Aldrete, and Ernesto Sahagún Flores. They would also like to thank Rogelio Troyo Sanromán for assistance with the statistical analysis.

References


Disease Markers


